Analysis of Agranulocytosis Time and Its Influencing Factors in Patients with Hematological Malignancies Treated with rhIL-11 combined rhG-CSF.
10.19746/j.cnki.issn.1009-2137.2022.03.043
- Author:
Han-Mei WEI
1
;
Zi-Jian LI
2
;
Li-Na WANG
3
Author Information
1. The First School of Clinical Medicine， The First Hospital of Lanzhou University， Lanzhou 730000， Gansu Province, China.
2. Department of Hematology， The First Hospital of Lanzhou University， Lanzhou 730000， Gansu Province, China,E-mail：ldyy_lizj@lzu.edu.cn.
3. Department of Hematology， The First Hospital of Lanzhou University， Lanzhou 730000， Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
agranulocytosis time;
hematological malignancy;
influencing factors;
recombinant human granulocyte-colony stimulating factor;
recombinant human interleukin-11
- MeSH:
Agranulocytosis;
Granulocyte Colony-Stimulating Factor/therapeutic use*;
Hematologic Neoplasms/drug therapy*;
Humans;
Interleukin-11;
Lymphoma, Non-Hodgkin/drug therapy*;
Recombinant Proteins/therapeutic use*;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(3):930-936
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the intervention effect of recombinant human interleukin-11 (rhIL-11) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) on the duration and severity of agranulocytosis in patients with hematological malignancies after chemotherapy, and to analyze the influencing factors.
METHODS:The data of hematological malignancy patients treated with rhIL-11 and rhG-CSF after chemotherapy in the hematology department of The First Hospital of Lanzhou University from July 2017 to July 2020 were collected retrospectively. The duration and differences of agranulocytosis in differeent groups were compared by univariate analysis, and the influencing factors of agranulocytosis duration were further analyzed by multiple regression analysis.
RESULTS:The duration of agranulocytosis in 97 patients was 6.47±2.93 days. The results of univariate analysis showed that there were no statistical differences in the duration of agranulocytosis among patients with different sex, age, height, weight, body surface area, body mass index (BMI), dose of rhG-CSF, dose of rhIL-11, spontaneous bleeding after administration of rhG-CSF and rhIL-11, and the duration of agranulocytosis in patients with different red blood cell count (RBC), hemoglobin(HGB) level, platelet count (PLT) and absolute neutrophil count (ANC), before administration of rhG-CSF and rhIL-11. There were significant differences in agranulocytosis time among patients with different disease types, chemotherapy cycle, fever after rhG-CSF and rhIL-11 administration, and different white blood cell count (WBC) baseline level before rhG-CSF and rhIL-11 administration (P＜0.05). Compared with patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), patients with acute myeloid leukemia (AML) had the longest duration of agranulocytosis, which was 7.07±3.05 d. Compared with patients with chemotherapy cycles of 4－6 and ≥7, patients with total chemotherapy cycle of 1－3 had the shortest duration of agranulocytosis, which was 5.25±2.48 d. Compared with patients without fever, patients with fever within 1 day after administration of cytokines and patients with fever within 2-5 days after administration of cytokines, the duration of agranulocytosis was the longest in patients with fever 6 days after administration of cytokines, which was 8.85±2.85 d. Compared with patients with WBC baseline <1.0×109/L, (1.0－1.9)×109/L and (2.0－3.9)×109/L, patients with WBC baseline ≥4.0×109/L had the shortest duration of agranulocytosis, which was 4.50±2.56 d. Multiple linear regression analysis showed that chemotherapy cycle, different fever after administration of rhG-CSF and rhIL-11, diagnosis of ALL and NHL, and WBC baseline level before administration of rhG-CSF and rhIL-11 were the influencing factors of the duration of agranulocytosis (P＜0.001).
CONCLUSION:The risk of prolonged agranulocytosis is higher in patients diagnosed with AML, with more chemotherapy cycles, lower WBC baseline before cytokines administration and fever later after cytokines administration, which should be paid more attention to.
